CTRI/2023/02/049928Not yet recruitingPhase 4
Efficacy and safety profile of Netarsudil 0.02% in in primary angle closure disease : A randomised comparative study
Advanced Eye Centre0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Primary angle closure spectrum of patients with Intraocular more than 21 mmHg will be randomised to receive both the drugs.
Exclusion Criteria
- •one eyed patient, secondary glaucomas, open angle glaucoma, previous history of angle surgeries, previous history of trabecular meshwork lasers
Investigators
Similar Trials
Not yet recruiting
Phase 4
Efficacy and safety of Netarsudil in primary angle closure glaucoma.CTRI/2023/08/056186Maharaja agrasen medical college
Completed
Phase 3
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular HypertensionOpen Angle GlaucomaOcular HypertensionNCT03284853Aerie Pharmaceuticals436
Active, not recruiting
Not Applicable
Efficacy and tolerability of nimesulide for the treatment of migraine attacks, a randomised, double blind, placebo controlled cross-over trialEUCTR2005-000583-28-ITHELSINN HEALTHCARE SA162
Not yet recruiting
Phase 3
Comparison between two medicines Netarsudil and Latanoprost for raised pressure of eyesCTRI/2023/12/060534Dr Rinky Thakur
Completed
Phase 4
Effect of Netarsudil vs Brimonidine in NTG Patients on LatanoprostNormal Tension GlaucomaNCT06449352Westlake Eye Specialists100